Market Overview

UPDATE: Piper Jaffray Raises PT to $11 on ISIS Pharmaceuticals on KYNAMRO Approval

Related ISIS
Isis Pharmaceuticals Earns $4M from Achaogen For The Initiation Of A Phase 3 Study Of Plazomicin
How Raytheon Company And General Dynamics Corporation Could Benefit From The ISIL Announcement
Making Money With Charles Payne: 08/29/14 (Fox Business)

Piper Jaffray maintained ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) with a Neutral rating and raised the price target from $9.00 to $11.00.

Piper Jaffray said, "The FDA approved KYNAMRO for Homozygous Familial Hypercholesterolemia (HoFH). As expected, the approval comes with a Boxed Warning for liver toxicity and a REMS program. ISIS is required to conduct 4 post marketing studies. This approval comes in the wake of the recent negative CHMP opinion for KYNAMRO's marketing authorization application (MAA) and therefore serves as an important validation of ISIS's antisense technology. We maintain our Neutral rating and are increasing our price target to $11 from $9 due to a reduced discount rate following KYNAMRO approval."

ISIS Pharmaceuticals closed at $13.38 on Tuesday.

Latest Ratings for ISIS

DateFirmActionFromTo
Aug 2014BMO CapitalMaintainsOutperform
Aug 2014Laidlow & Co.Initiates Coverage onBuy
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters